Minimal evolution time and quantum speed limit of non-Markovian open systems

by Meng, Xiangyi, Wu, Chengjun, Guo, Hong
Published 2015

Rivastigmine in moderately severe-to-severe Alzheimer’s disease: Severe Impairment Battery factor analysis

by Ferris, Steven, Karantzoulis, Stella, Somogyi, Monique, Meng, Xiangyi
Published 2013

Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia

by Farlow, Martin R., Schmitt, Frederick, Aarsland, Dag, Grossberg, George T., Somogyi, Monique, Meng, Xiangyi
Published 2013

Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies

by Kircik, Leon, Fowler, Joseph, Weiss, Jonathan, Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Published 2016

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

by Menter, Alan, Cather, Jennifer C., Jarratt, Michael, Meng, Xiangyi, Guana, Adriana, Nyirady, Judit
Published 2016

Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer’s disease

by Micca, Joseph L, Galvin, James E, Velting, Drew M, Meng, Xiangyi
Published 2014

A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia

by Farlow, Martin R, Grossberg, George T, Sadowsky, Carl H, Meng, Xiangyi, Somogyi, Monique
Published 2013